Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Research

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

Yoon K. Loke, Sonal Singh and Curt D. Furberg
CMAJ January 06, 2009 180 (1) 32-39; DOI: https://doi.org/10.1503/cmaj.080486
Yoon K. Loke MBBS MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonal Singh MD MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Curt D. Furberg MD PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Abstract

Background: Rosiglitazone and pioglitazone may increase the incidence of fractures. We aimed to determine systematically the risk of fractures associated with thiazolidinedione therapy and to evaluate the effect of the therapy on bone density.

Methods: We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), other trial registries and product information sheets through June 2008. We selected long-term (≥ 1 year) randomized controlled trials involving patients with type 2 diabetes and controlled observational studies that described the risk of fractures or changes in bone density with thiazolidinediones. We calculated pooled odds ratios (ORs) for fractures and the weighted mean difference in bone density.

Results: We analyzed data from 10 randomized controlled trials involving 13 715 participants and from 2 observational studies involving 31 679 participants. Rosiglitazone and pioglitazone were associated with a significantly increased risk of fractures overall in the 10 randomized controlled trials (OR 1.45, 95% confidence interval [CI] 1.18–1.79; p < 0.001). Five randomized controlled trials showed a significantly increased risk of fractures among women (OR 2.23, 95% CI 1.65–3.01; p < 0.001) but not among men (OR 1.00, 95% CI 0.73–1.39; p = 0.98). The 2 observational studies demonstrated an increased risk of fractures associated with rosiglitazone and pioglitazone. Bone mineral density in women exposed to thiazolidinediones was significantly reduced at the lumbar spine (weighted mean difference –1.11%, 95% CI –2.08% to –0.14%; p = 0.02) and hip (weighted mean difference –1.24%, 95%CI –2.34% to –0.67%; p < 0.001) in 2 randomized controlled trials.

Interpretation: Long-term thiazolidinedione use doubles the risk of fractures among women with type 2 diabetes, without a significant increase in risk of fractures among men with type 2 diabetes.

View Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 180 (1)
CMAJ
Vol. 180, Issue 1
6 Jan 2009
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Yoon K. Loke, Sonal Singh, Curt D. Furberg
CMAJ Jan 2009, 180 (1) 32-39; DOI: 10.1503/cmaj.080486

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Yoon K. Loke, Sonal Singh, Curt D. Furberg
CMAJ Jan 2009, 180 (1) 32-39; DOI: 10.1503/cmaj.080486
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Interpretation
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights
  • Dans ce numéro
  • Thiazolidinediones: Do harms outweigh benefits?
  • PubMed
  • Google Scholar

Cited By...

  • Use of Antihyperglycemic Medications in U.S. Adults: An Analysis of the National Health and Nutrition Examination Survey
  • Ligand-Dependent Corepressor (LCoR) Is a Rexinoid-Inhibited Peroxisome Proliferator-Activated Receptor {gamma}-Retinoid X Receptor {alpha} Coactivator
  • Fracture risk associated with common medications used in treating type 2 diabetes mellitus
  • Associations with fracture in patients with diabetes: a nested case-control study
  • Thiazolidinedione-induced lipid droplet formation during osteogenic differentiation
  • Update on Safety Issues Related to Antihyperglycemic Therapy
  • Validity of Meta-analysis in Diabetes: Meta-analysis Is an Indispensable Tool in Evidence Synthesis
  • Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013
  • Interpreting Adverse Signals in Diabetes Drug Development Programs
  • Nuclear Receptors and Their Selective Pharmacologic Modulators
  • Intensive Glycemic Control Is Not Associated With Fractures or Falls in the ACCORD Randomized Trial
  • Glycemic Control Over 5 Years in 4,900 People With Type 2 Diabetes: Real-world diabetes therapy in a clinical trial cohort
  • Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: systematic review and meta-analysis
  • Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies
  • Type 2 Diabetes: Uses of thiazolidinediones and insulin
  • Selective peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) modulation as a strategy for safer therapeutic PPAR{gamma} activation
  • Peroxisome proliferator-activated receptor translational research and clinical experience
  • Low Serum Level of the Endogenous Secretory Receptor for Advanced Glycation End Products (esRAGE) Is a Risk Factor for Prevalent Vertebral Fractures Independent of Bone Mineral Density in Patients With Type 2 Diabetes
  • Rosiglitazone was non-inferior to metformin plus sulphonylurea for CV events but increased risk of HF and fractures in type 2 diabetes
  • Beware fractures
  • Thiazolidinedione use and the risk of fractures
  • Thiazolidinedione use and the risk of fractures
  • Two of the authors respond:
  • Rosiglitazone, Pioglitazone, and Fractures: A Meta-Analysis
  • Thiazolidinediones: Do harms outweigh benefits?
  • Google Scholar

More in this TOC Section

  • Association between long-term exposure to ambient air pollution and COVID-19 severity: a prospective cohort study
  • The risk of death or unplanned readmission after discharge from a COVID-19 hospitalization in Alberta and Ontario
  • The link between medical conditions and fatal drownings in Canada: a 10-year cross-sectional analysis
Show more Research

Similar Articles

Collections

  • Topics
    • Diabetes
    • Drugs: adverse reactions

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire